to a sometimes fatal pseudomembranous colitis (PMC). Recent data indicate that this microorganism is almost invariably involved in PMC and accounts for about one-fourth to one-third of all cases of antibiotic-associated diarrhea in which endoscopic examination does not show any pseudomembrane or plaque (C. difficile-associated diarrhea) (16) . Antimicrobial agents most commonly implicated as inciting factors of both C. difficile intestinal colonization and disease are clindamycin, cephalosporins, and ampicillin (1-3, 9, 14, 17, 26) . C. difficile, however, has also been isolated from the inanimate hospital environment, especially in areas with patients known to harbor the microorganism and from individuals who are in contact with symptomatic patients. Moreover, nosocomial spread and cross infection have recently been extensively documented (1, 5, 10, 21), suggesting the possibility of enteric isolation for carriers and symptomatic cases. Prevention of outbreaks can, however, also successfully be achieved by using suitable antibiotics to eliminate gut colonization by toxigenic strains.
C. difficile isolates are highly susceptible in vitro to many antimicrobial agents, including vancomycin, metronidazole, bacitracin, rifampin (13) , and amoxycillin-clavulanic acid (6) , and several studies document the effectiveness of oral vancomycin (12, 16, 24, 28) , metronidazole (8, 27) , and bacitracin (29) . Generally, vancomycin is considered the drug of choice for the treatment of PMC (11, 19, 24, 28) , with metronidazole and bacitracin as useful alternatives (22) . Recently, in clinical situations in which enteral therapy has not been possible, intravenous metronidazole has been advocated (20) . The clinical response to vancomycin treatment is usually very good and prompt, with a reduction in severity of diarrhea within 48 to 72 h (12) . Relapse after vancomycin therapy has, however, been reported in 14 to 20% of patients (4, 12, 24) , and posttreatment asymptomatic carriage of C. difficile is even more common, occurring in as many as 28% of patients (12) . Teicoplanin, a new glycopeptide antibiotic, is very active in vitro against C. difficile isolates (22, 23) .
However, teicoplanin treatment of some cases of PMC in humans has previously been reported only by us and as preliminary data (10a). Here we report our experience using vancomycin (patients hospitalized in the period from Febru-* Corresponding author. ary 1984 to February 1987) and teicoplanin (given since March 1987, when this drug was first available in Italy) as therapy for PMC and C. difcile-associated diarrhea in a larger cohort of patients.
In this study, C. difficile-associated diarrhea and PMC were diagnosed by demonstrating both C. difficile and cytotoxin in the feces of symptomatic patients, i.e., in patients passing more than three loose stools per day and in the absence of other recognized intestinal pathogens. The diagnosis of PMC was based also on the colonoscopic demonstration of the typical endoscopic picture. For isolation of C.
difficile, stool samples were cultured anaerobically by direct plating on CD Selective Blood Agar (Oxoid Ltd., Basingstoke, United Kingdom) supplemented with cycloserine (250 pLg/ml) and cefoxitin (8 p.g/ml) after heat shock (80°C for 10 min) and in enrichment broth (7) . The broth was subcultured on CD Selective Agar after 24 h. The microorganism was identified by colony morphology, gas-liquid chromatography, and biochemical tests according to criteria given in the Anaerobe Labor-ator-y Maniial of Virginia Polytechnic Institute (18) . The in vitro susceptibilities of C. difficile isolates were determined by the agar dilution method (25) patients were instructed to contact the infectious diseases consultant if diarrhea or any other intestinal disturbances occurred.
In the period of our study, C. difficile culture and cytotoxin assay were positive in 47 symptomatic patients. A total of 39 patients (19 in the vancomycin group and 20 in the teicoplanin group) underwent colonoscopy, and typical endoscopic appearances of PMC were seen in 15 and 20 patients, respectively. Endoscopy was not performed in six subjects receiving vancomycin and in two given teicoplanin. A total of 25 patients (13 males and 12 females) were treated with vancomycin, and 22 (12 males and 10 females) received teicoplanin. The main features of the two treatment groups, as well as the responses to therapy, are shown in Table 1 . In the vancomycin group, two patients died (on days 2 and 3 of treatment) as a result of the underlying disease. Clinical symptoms recurred in 3 of 23 evaluable patients after discontinuation of therapy. Furthermore, follow-up cultures from another asymptomatic patient were positive. These patients underwent a second course of vancomycin, and all were cleared of C. difficile 10 days after discontinuation of therapy. All patients treated with teicoplanin remained asymptomatic, and all but one were also cleared of C.
difficile. Clinical response to each drug was very good, with a decrease in diarrhea within 24 to 48 h. No side effects related to vancomycin or teicoplanin treatment were observed. The most favorable MICs for C. difficile among the assayed antibiotics were of teicoplanin ( Table 2) .
The results of our teicoplanin therapy (no clinical relapse and only one asymptomatic carriage after treatment in 22 symptomatic cases) seem very encouraging. However, prospective, comparative, randomized trials between vancomycin and teicoplanin are needed in order to define the role of teicoplanin in the treatment of C. difficile-associated disease. 
